7,000. That’s the estimated number of distinct types of rare and genetic diseases affecting more than 400 million people around the world. Yet 95% of rare diseases lack an FDA-approved product for treatment.1 Even with the Orphan Drug Act, there are many daunting barriers that stand between researchers and results. Read how de-identified, real-world data (RWD) – featuring claims and electronic health record (EHR) data – creates a remarkable opportunity to fill the data divide, power development and demonstrate the effectiveness of treatment options. Download the whitepaper here.